Published in Cancer Weekly, December 30th, 2003
The research from Queen Mary, University Of London, and presented for the first time at the 26th San Antonio (Texas) Breast Cancer Symposium, helps to explain reported clinical benefit rates of over 50% and differentiates Modrenal's mechanism of action from existing therapies, such as tamoxifen and the aromatase inhibitors.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.